August 2012 Blog Posts (10)

Targeted Educational Approach Teaches Young Patients to Remain Motionless During MRI Scans

A new educational approach helps children with sickle cell disease complete MRI tests without sedation. Sitting still is tough for young children, making MRI scans a challenge. The scans require that patients remain motionless for extended periods. Findings from St. Jude Children's Research Hospital showed that a brief, targeted intervention dramatically increases the likelihood that children as young as 5 years old will be able to undergo testing without sedation.

That is…


Added by Peter Hofland, PhD on August 31, 2012 at 8:30am — No Comments

Nationally Televised Fundraising Event "Stand Up To Cancer" (SU2C) Airs Commercial-Free on All Major Networks

Stand Up To Cancer (SU2C), a program of the Entertainment Industry Foundation (EIF) aiming to raise funds to hasten the pace of groundbreaking translational research in cancer, earlier today announced that Hollywood is once again rallying together and lending its support to the third SU2C primetime television fundraising special. The event will air simultaneously on all major networks in the United States, on Friday, September…


Added by Peter Hofland, PhD on August 22, 2012 at 5:30am — No Comments

New iPhone App Encourages Women to be Proactive with Breast Self-exams

The National Breast Cancer Foundation, Inc.® (NBCF) earlier today announced the official launch of its Early Detection Plan (EDP), a new free iPhone app designed to encourage women to become more proactive about their health by scheduling reminders via push notifications to perform routine breast self-exams and schedule clinical…


Added by Peter Hofland, PhD on August 21, 2012 at 5:00pm — No Comments

Patient Enrollment Completed in Phase I Trial Investigating Reolysin® in Combination with FOLFIRI in Patients with Colorectal Cancer

Reovirus (Reolysin®; Oncolytics BiotechCalgary, AB, Canada), a proprietary variant of the Respiratory Enteric Orphan Virus, is a benign, double-stranded RNA human virus with oncolytic properties. In a variety of clinical trials, the virus has shown to selectively kill tumor cells with activated signaling through the RAS pathway.

The RAS protein family members belong to a class of protein called…


Added by Peter Hofland, PhD on August 16, 2012 at 5:30am — No Comments

Study Shows Stress Promotes Breast Cancer Cell Colonization of Bones

Stress can promote breast cancer cell colonization of bones, Vanderbilt Center for Bone Biology investigators have discovered. The preclinical studies, reported on July 17 in PLoS Biology, demonstrate that activation of the sympathetic nervous system, which is active in response to stress, primes the bone environment for breast cancer cell metastasis.

In addition, the…


Added by Peter Hofland, PhD on August 9, 2012 at 2:00pm — No Comments

Why Prostate Cancer Management Should Emphasize Healthy Lifestyle Changes

Men diagnosed with prostate cancer are less likely to die from the disease than from largely preventable conditions such as heart disease. A new study from Harvard School of Public Health which looks at causes of death among men with prostate cancer suggests that encouraging healthy lifestyle changes should play an important role in prostate cancer management.

Mara Epstein, a postdoctoral…


Added by Peter Hofland, PhD on August 9, 2012 at 1:30pm — No Comments

Genetically-induced IDO Inhibitors Reduce Lung Tumor Burden and Improve Survival

Inhibitors of indoleamine 2,3-dioxygenase (IDO), a tryptophan-catabolizing enzyme that induces immune tolerance, are being assessed in clinical trials as a potential treatment for recurrent or refractory solid tumors. Clear genetic rationale for these trials, together with evidence that primary and metastatic lung tumors might be particularly susceptible to the drugs, is now reported in a preclinical study published in…


Added by Peter Hofland, PhD on August 8, 2012 at 4:00pm — No Comments

European Medicines Agency Approves Decitabine for Older Patient with Newly Diagnosed De Novo or Secondary AML

Early in July, the European Medicines Agency Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product decitabine (Dacogen®), Janssen-Cilag), 50 mg, powder for concentrate for solution for infusion, intended for the treatment of acute myeloid leukemia…


Added by Peter Hofland, PhD on August 7, 2012 at 5:00pm — No Comments

Aflibercept Approved After Priority Review for Treatment of Previously Treated Metastatic Colorectal Cancer

The U.S. Food and Drug Administration (FDA) approved ZALTRAP® (ziv-aflibercept, Sanofi and Regeneron Pharmaceuticals, Inc) Injection for Intravenous Infusion, in combination with 5-fluorouracil, leucovorin, irinotecan (FOLFIRI), for patients with metastatic colorectal cancer (mCRC) that is resistant to or has progressed following an oxaliplatin-containing regimen.

"Colorectal cancer is one of the deadliest cancers and is responsible for more than half a million deaths…


Added by Peter Hofland, PhD on August 3, 2012 at 1:30pm — No Comments

A Worthwhile Initiative Helps Create the first Rare Cancers Access Index

More than 4 million people in the European Union are affected by rare cancers. Rare diseases are generally defines as diseases with a prevalence of less than 50 patients per 100,000 people per year. A more conservative definition, which takes a number of particularities of natural history and prognosis into account (including the incidence of a cancers with less than 5 patients per 100,000 people per year), suggests that rare cancers represent about 22% of all malignant neoplasm…


Added by Peter Hofland, PhD on August 1, 2012 at 12:30pm — No Comments

Monthly Archives














Register for free to view all the Onco'Zine - The International Oncology Network content:


Onco'Zine is present here

Bookmark / Share



© 2017   Created by Peter Hofland, PhD.   Powered by

Badges  |  Report an Issue  |  Terms of Service

Find us on Google+